† Adverse events occurring in at least 2% of patients treated with memantine ER and at a rate that is higher than in the placebo group. SIB: significant benefit for memantine (LSMD: 2.6; 95% CI: 1.0–4 ...

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...

Association of anticonvulsant prophylaxis in patients with primary and metastatic brain tumors and 1-year overall survival: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from ...

Steven T. DeKosky and Bengt Winblad led this live discussion on how the addition of memantine to the clinician's toolbox will change the management of Alzheimer's disease. Following its FDA approval ...

Actavis and Adamas Pharmaceuticals Inc announced that the US Food and Drug Administration (US FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine ...

Allergan plc (NYSE: AGN), today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement ...

Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type NEW YORK, Jun 21, 2010 (BUSINESS WIRE ...

Please provide your email address to receive an email when new articles are posted on . Response rates on the SRS-2 and CGI-S were significantly higher in those given memantine. Memantine was also ...

† Noted adverse events were experienced in ≥5% of either treatment group, and had an incidence more than or equal to twice as great in memantine-treated patients than in placebo-treated patients. AE: ...